SCHEMBL95599

SCHEMBL95599

[CH2]c1ccc(C(=O)Nc2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.75
RAB9A P51151 5/20 0.75
MEN1 O00255 5/20 0.75
KMT2A Q03164 5/20 0.75
MAPT P10636 4/20 0.75
KDM4E B2RXH2 2/20 0.75
PKM P14618 1/20 0.75
LMNA P02545 2/20 0.67
POLB P06746 2/20 0.67
MAPK1 P28482 1/20 0.67
BCAT2 O15382 1/20 0.58
EPHX1 P07099 1/20 0.58
EPHX2 P34913 1/20 0.58
MAOB P27338 3/20 0.57
MAOA P21397 1/20 0.56
KCNQ3 O43525 1/20 0.54
KCNQ2 O43526 1/20 0.54
KCNE1 P15382 1/20 0.54
KCNQ1 P51787 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089807 0.90 MEN1 (0.75) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL95034 0.87 MAPT (0.58) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL2681347 0.86 NPC1 (0.80) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL94560 0.86 NPC1 (0.73) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL97523 0.86 NPC1 (0.60) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL6557523 0.85 NPC1 (0.77) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL8460312 0.85 NPC1 (0.78) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL10192062 0.83 NPC1 (0.75) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL6078205 0.83 NPC1 (0.75) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL16589430 0.83 NPC1 (0.75) NPC1RAB9AMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB NPC1 2361/4885RAB9A 3886/4885MEN1 4401/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 NPC1 2922/4885RAB9A 2273/4885MEN1 3912/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 NPC1 2922/4885RAB9A 2273/4885MEN1 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.